Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP177013.RA2HKLQRQgn536cQCHNXJoT2dLO-SYFqHX8dKxZsF8-vA130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP177013.RA2HKLQRQgn536cQCHNXJoT2dLO-SYFqHX8dKxZsF8-vA130_assertion type Assertion NP177013.RA2HKLQRQgn536cQCHNXJoT2dLO-SYFqHX8dKxZsF8-vA130_head.
- NP177013.RA2HKLQRQgn536cQCHNXJoT2dLO-SYFqHX8dKxZsF8-vA130_assertion description "[Carriers of the APOE E2 SNP had a significantly lower risk of CHD hazard ratio (HR) of 0.63 (95% confidence interval CI: 0.42-0.95), as did carriers of the APOC2 SNP rs5127 (HR = 0.72, 95% CI: 0.56-0.93), while carriers of APOC1 SNP rs4803770 had higher risk of CHD (HR = 1.36, 95% CI: 1.04-1.78) compared with noncarriers.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP177013.RA2HKLQRQgn536cQCHNXJoT2dLO-SYFqHX8dKxZsF8-vA130_provenance.
- NP177013.RA2HKLQRQgn536cQCHNXJoT2dLO-SYFqHX8dKxZsF8-vA130_assertion evidence source_evidence_literature NP177013.RA2HKLQRQgn536cQCHNXJoT2dLO-SYFqHX8dKxZsF8-vA130_provenance.
- NP177013.RA2HKLQRQgn536cQCHNXJoT2dLO-SYFqHX8dKxZsF8-vA130_assertion SIO_000772 20498921 NP177013.RA2HKLQRQgn536cQCHNXJoT2dLO-SYFqHX8dKxZsF8-vA130_provenance.
- NP177013.RA2HKLQRQgn536cQCHNXJoT2dLO-SYFqHX8dKxZsF8-vA130_assertion wasDerivedFrom gad-20150221 NP177013.RA2HKLQRQgn536cQCHNXJoT2dLO-SYFqHX8dKxZsF8-vA130_provenance.
- NP177013.RA2HKLQRQgn536cQCHNXJoT2dLO-SYFqHX8dKxZsF8-vA130_assertion wasGeneratedBy ECO_0000203 NP177013.RA2HKLQRQgn536cQCHNXJoT2dLO-SYFqHX8dKxZsF8-vA130_provenance.